Literature DB >> 27412207

Intranasal midazolam for seizure cessation in the community setting.

Michal Zelcer, Ran D Goldman.   

Abstract

QUESTION: There are times when parents arrive to my clinic after their child has had a seizure and a second seizure takes place in the clinic. While waiting for transport to the hospital, are there ways to stop the seizures without the need to obtain intravenous access in the clinic? ANSWER: Intravenous diazepam has been a first-line therapy to stop seizures in children for many years. Other routes of drug administration such as intramuscular, rectal, and buccal are available but have several limitations. More evidence suggests that the intranasal route to administer drugs is quick and effective in children, and the use of midazolam has been continuing to show promise in seizure cessation. With its good safety profile, intranasal midazolam can be used in the clinic and prehospital setting for seizure cessation in children. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27412207      PMCID: PMC4955082     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  21 in total

Review 1.  The assessment of topical nasal drug distribution.

Authors:  R Aggarwal; A Cardozo; J J Homer
Journal:  Clin Otolaryngol Allied Sci       Date:  2004-06

Review 2.  Intranasal drug delivery: how, why and what for?

Authors:  Anaísa Pires; Ana Fortuna; Gilberto Alves; Amílcar Falcão
Journal:  J Pharm Pharm Sci       Date:  2009       Impact factor: 2.327

3.  Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy.

Authors:  Maija Holsti; Nanette Dudley; Jeff Schunk; Kathleen Adelgais; Richard Greenberg; Cody Olsen; Aaron Healy; Sean Firth; Francis Filloux
Journal:  Arch Pediatr Adolesc Med       Date:  2010-08

4.  Preanesthetic sedation of preschool children using intranasal midazolam.

Authors:  N C Wilton; J Leigh; D R Rosen; U A Pandit
Journal:  Anesthesiology       Date:  1988-12       Impact factor: 7.892

5.  Nasal midazolam and ketamine for paediatric sedation during computerised tomography.

Authors:  A Louon; V G Reddy
Journal:  Acta Anaesthesiol Scand       Date:  1994-04       Impact factor: 2.105

Review 6.  Intranasal therapies for acute seizures.

Authors:  Reetta Kälviäinen
Journal:  Epilepsy Behav       Date:  2015-05-26       Impact factor: 2.937

7.  Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study.

Authors:  Tunç Fişgin; Yavuz Gurer; Tahsin Teziç; Nesrin Senbil; Pelin Zorlu; Cetin Okuyaz; Deniz Akgün
Journal:  J Child Neurol       Date:  2002-02       Impact factor: 1.987

8.  Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study.

Authors:  E Lahat; M Goldman; J Barr; T Bistritzer; M Berkovitch
Journal:  BMJ       Date:  2000-07-08

9.  Design and phenomenology of the FEBSTAT study.

Authors:  Dale C Hesdorffer; Shlomo Shinnar; Darrell V Lewis; Solomon L Moshé; Douglas R Nordli; John M Pellock; James MacFall; Ruth C Shinnar; David Masur; L Matthew Frank; Leon G Epstein; Claire Litherland; Syndi Seinfeld; Jacqueline A Bello; Stephen Chan; Emilia Bagiella; Shumei Sun
Journal:  Epilepsia       Date:  2012-06-28       Impact factor: 5.864

10.  Prehospital intranasal midazolam for the treatment of pediatric seizures.

Authors:  Maija Holsti; Benjamin L Sill; Sean D Firth; Francis M Filloux; Steven M Joyce; Ronald A Furnival
Journal:  Pediatr Emerg Care       Date:  2007-03       Impact factor: 1.454

View more
  5 in total

Review 1.  Association of Child Neurology-Indian Epilepsy Society Consensus Document on Parental Counseling of Children with Epilepsy.

Authors:  Kavita Srivastava; Rachna Sehgal; Ramesh Konanki; Ridhimaa Jain; Suvasini Sharma; Rekha Mittal; Anaita Hedge; Anju Aggarwal; Arijit Chattopadhyay; Bijoy Patra; Jaya Shankar Kaushik; Lokesh Lingappa; Naveen Sankhyan; Puja Kapoor; Pratibha Singhi; Satinder Aneja; Sheffali Gulati; Sujata Kanhere; Surekha Rajadhyakshya; Veena Kalra; Vineet Bhushan Gupta; Vrajesh Udani; Yeeshu Sudan; Man Mohan Mehendiratta; Manjari Tripathi; G T Subhash; Bhavneet Bharti; Srinivas Rao; Munawwar Naseem; Snehashish Mukherjee; Priya Jain; Mehreen Khosla; Kavita Shanbagh; Deepa Jain; Sumeet Mansingh; Dhaneshwar Yadav; Chetan Singh; Sunita Raina; Sapna Srivastava; Leena Ahuja; Rashmi Kumar; K P Vinayan; Rakesh Jain; Satish Jain; Devendra Mishra
Journal:  Indian J Pediatr       Date:  2019-06-08       Impact factor: 1.967

Review 2.  Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life.

Authors:  Ahsan Azhar; David Hui
Journal:  Cancer Res Treat       Date:  2022-06-30       Impact factor: 5.036

3.  Alleviation of Oxidative Damage and Involvement of Nrf2-ARE Pathway in Mesodopaminergic System and Hippocampus of Status Epilepticus Rats Pretreated by Intranasal Pentoxifylline.

Authors:  Yunxiao Kang; Wensheng Yan; Hui Fang; Guoliang Zhang; Yakun Du; Lei Wang; Huixian Cui; Geming Shi
Journal:  Oxid Med Cell Longev       Date:  2017-03-12       Impact factor: 6.543

4.  Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study.

Authors:  Marios Charalambous; Holger A Volk; Andrea Tipold; Johannes Erath; Enrice Huenerfauth; Antonella Gallucci; Gualtiero Gandini; Daisuke Hasegawa; Theresa Pancotto; John H Rossmeisl; Simon Platt; Luisa De Risio; Joan R Coates; Mihai Musteata; Federica Tirrito; Francesca Cozzi; Laura Porcarelli; Daniele Corlazzoli; Rodolfo Cappello; An Vanhaesebrouck; Bart J G Broeckx; Luc Van Ham; Sofie F M Bhatti
Journal:  J Vet Intern Med       Date:  2019-10-03       Impact factor: 3.333

Review 5.  Strategies to Improve Drug Strength in Nasal Preparations for Brain Delivery of Low Aqueous Solubility Drugs.

Authors:  Patrícia C Pires; Márcio Rodrigues; Gilberto Alves; Adriana O Santos
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.